KFDA approves Retisert for treatment of affecting posterior segment of eye
Published: 2008-01-07 06:57:00
Updated: 2008-01-07 06:57:00
The Korea Food and Drug Administration says it has approved Bausch & Lomb's Retisert (fluocinolone acetonide) 0.59 mg, the world's first intravitreal drug implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Uveitis is one of the leading cause...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
